1. Radical New Concepts in Lipid Management

2. 2013 United States Cholesterol Guidelines vs ESC/EAS Guidelines for the Management of Dyslipidemias

3. Statin Therapy

4. ESC Categories of Individuals at High Risk

5. ESC Recommendations for Patients at Very High Risk

6. Randomized Controlled Studies Failing to Show Evidence of Further Reduced Risk When Adding a Nonstatin

7. IMPROVE-IT

8. On Statin Levels and Risk for CV Events

9. IMPROVE-IT Safety End Points

10. IMPROVE-IT

11. PCSK9 Monoclonal Antibodies

12. Baseline Characteristics Phase 3 Placebo-Controlled Trials

13. Post-hoc Adjudicated Cardiovascular TEAEs† Pooled From Phase 3 Placebo-Controlled Trials

14. ODYSSEY Long-term Safety Results

15. PCSK9 Loss-of-Function Mutations

16. TEAEs Comparable in Patients With 2 Consecutive LDL-C < 25 mg/dL

17. Safety Analysis Including All Data Collected Until Last Patient Visit at Week 52

18. PCSK9 Priority Patient Targets

19. Abbreviations

20. Abbreviations (cont)

21. Abbreviations (cont)

22. References

23. References (cont)

24. References (cont)

25. References (cont)